Fasoracetam

Metabotropic Glutamate Receptor (mGluR) Modulation#

Fasoracetam's signature mechanism — and what separates it from piracetam-family racetams — is broad-spectrum activity across all three groups of metabotropic glutamate receptors: Group I (mGluR1/5), Group II (mGluR2/3), and Group III (mGluR4/6/7/8). Rather than flooring or blocking glutamate transmission, it modulates it. The Group II/III activity in particular dampens excess presynaptic glutamate release, which is the proposed substrate for the anxiolytic and anti-anhedonic effects users report. This is also the mechanism the CHOP investigators built the ADHD program around, specifically targeting adolescents carrying CNVs in mGluR network genes.

"Fasoracetam was well tolerated at all doses up to 400 mg BID and resulted in improvement in CGI-I and CGI-S scores in subjects with ADHD carrying mGluR network gene variants." — Elia J, Ungal G, Kao C, et al., Nature Communications (2018)

Practical translation: the focus effect is not stimulant-like. It shows up as reduced anxious rumination and smoother cognitive throughput — the absence of noise rather than the presence of drive.

GABA-B Receptor Upregulation#

Repeated dosing increases GABA-B receptor density in cortex and hippocampus in rodent models. This is an adaptive upregulation, not direct agonism — fasoracetam is not a GABA-B agonist in the phenibut/baclofen sense, which is why it doesn't produce the sedation, euphoria, or dependence liability of those compounds.

"Repeated administration of fasoracetam increased the number of GABA(B) receptors in rat cerebral cortex and hippocampus, suggesting a mechanism for its anxiolytic and cognitive effects." — Malykh AG, Sadaie MR., Drugs (2010)

This is the mechanistic rationale for the community's most specific use case: restoring GABA-B tone after chronic phenibut or baclofen exposure has downregulated the receptor population. It's also why anxiolysis from fasoracetam builds over days-to-weeks rather than appearing acutely after the first dose — receptor density changes are not same-day events.

Cholinergic Downstream Signalling#

Older Nippon Shinyaku work on NS-105 (fasoracetam's original code) showed enhanced acetylcholine release in cortex and hippocampus, along with partial reversal of baclofen-induced memory deficits in rodents. This is the classical "racetam" cognitive signature — improved working memory and recall consolidation mediated through cholinergic tone. It's also why a choline source (alpha-GPC 300mg or CDP-choline 250mg) is routinely co-administered: the increased ACh turnover can deplete substrate and produce the classic racetam headache when choline is marginal.

Glutamate–GABA Axis Balancing#

The combined mGluR dampening of excess glutamate and the GABA-B upregulation of inhibitory tone is why fasoracetam is often described as a "smoothing" compound rather than a stimulating or sedating one. For the looksmaxxing and nootropics audience running high-dose caffeine, phenylpiracetam, clenbuterol, or ADHD stimulants, this axis matters — stimulant-driven glutamate excess is what produces the jitter, the rumination, and the stimulant "edge." Fasoracetam's mechanism addresses both sides of that imbalance simultaneously, which is the reason it stacks so well with phenylpiracetam and with morning caffeine protocols.

Clinical Signal and Mechanistic Caveats#

The mechanism is real and reproducible in animal models, and the CHOP open-label signal in mGluR-variant ADHD was genuine. However, the subsequent Phase 2 programs (NCT03265119, NCT03609619) failed their primary endpoints, and Aevi discontinued development. The honest mechanistic reading: fasoracetam is a genuine mGluR modulator and GABA-B upregulator, but response is highly variable and appears to track mGluR genetic status. Responders tend to know within two weeks. Non-responders escalating dose will not convert themselves into responders — they will convert themselves into headache cases. The inverted-U dose-response typical of mGluR modulators is why the community sweet spot (20–100 mg) sits an order of magnitude below the clinical ADHD dose (up to 800 mg/day).

Common (most users)#

• Headache — the most frequent complaint and almost always dose-related. Mitigated by co-administering a choline source (alpha-GPC 300mg or CDP-choline 250mg) with each dose, and by keeping per-administration doses in the 20–50mg window rather than chasing the clinical trial's 400mg BID.
• Mild fatigue or sedation — more common at initiation and at higher doses, consistent with GABA-B upregulation. Shifting the second dose earlier in the day (no later than 4pm) typically resolves it.
• Transient GI upset — uncommon, usually resolves within the first week. Sublingual administration sidesteps this almost entirely.
• Emotional flattening / "brain fog" — signal to reduce the dose rather than push through. The dose–response curve is inverted-U; more is not better above ~100mg per administration.
• Vivid dreams — anecdotal, not well documented, generally benign.

Uncommon (dose-dependent or individual)#

• Paradoxical anxiety or irritability — typically appears above 100mg per administration or in non-responders. Back off to 20mg and reassess after a week; if the signal persists, fasoracetam is likely not the right mGluR modulator for that user.
• Anhedonia / motivational flattening on long runs — effects plateau or invert after 6–8 weeks continuous. A 1–2 week washout restores the profile.
• Sleep disruption — almost exclusively from late-afternoon or evening dosing. The 4–6.5h half-life means AM + early-afternoon administration keeps coverage out of the sleep window.
• Stacking-induced sedation — when combined with other GABAergic agents (alcohol, gabapentinoids, high-dose l-theanine), the GABA-B upregulation amplifies sedative load. Reduce fasoracetam first.

No routine bloodwork is required — fasoracetam does not perturb lipids, liver enzymes, renal markers, or hormones at documented doses. An annual CBC/CMP is sufficient for anyone running chronic nootropic stacks.

Rare but serious#

• Bradycardia — documented in a single overdose case report involving combined fasoracetam + phenibut, with heart rate dropping to 34–50 bpm and requiring atropine and pacing pads.

"Bradycardia resolved after atropine and discontinuation of both drugs, confirming additive CNS and cardiac depression with combined phenibut and fasoracetam overdose." — Merchan et al., J Clin Intensive Care Med (2016)

• Profound CNS depression — same overdose context. Warning signs include excessive sedation, slowed respiration, and bradycardia; discontinue immediately and seek emergency care.
• Theoretical seizure-threshold effects — no cases reported in the trial literature, but glutamatergic modulators have not been studied in epileptic cohorts. Any new seizure activity is a hard stop.

Hard contraindications#

• Concurrent phenibut, baclofen, or GHB. Mechanistically redundant on GABA-B and toxicologically additive. This is the single most important contraindication and the reason the Merchan case report exists. Fasoracetam is used to reset GABA-B tone after phenibut discontinuation — never alongside active dosing.
• Seizure disorders. No trial data in epileptic populations; glutamatergic modulation carries a theoretical risk not worth taking.
• Pregnancy and lactation. No safety data; avoid.
• MAOI co-administration. No interaction data; the theoretical glutamatergic load warrants avoidance.

Gender and PCT considerations#

Fasoracetam is non-hormonal — no activity at androgen, estrogen, or progesterone receptors, no HPG-axis suppression, and no impact on menstrual cycle, fertility, or semen parameters. Dosing is identical across the subject pool and the compound is considered safe for female users at the same dose ranges. No PCT is required and none of the ancillary concerns that accompany AAS or SARM cycles apply here — the only "cycle" management is the 1–2 week washout every 6–8 weeks to preserve responsiveness.